|
Chemotherapy for
metastatic disease: Select publications |
Ahn J et al. Phase II study of gemcitabine and
capecitabine in patients with metastatic breast
cancer pretreated with anthracyclines and
taxanes. Proc ASCO 2005;Abstract 895.
Alba E et al; Spanish Breast Cancer Research
Group. Multicenter randomized trial comparing
sequential with concomitant administration of
doxorubicin and docetaxel as first-line treatment
of metastatic breast cancer: A Spanish Breast
Cancer Research Group (GEICAM-9903) phase
III study. J Clin Oncol 2004;22(13):2587-93.
Abstract
Albain KS et al. Global phase III study of
gemcitabine plus paclitaxel (GT) vs paclitaxel
(T) as frontline therapy for metastatic breast
cancer (MBC): First report of overall survival. Proc ASCO 2004;Abstract 510.
Andres R et al. Gemcitabine/capecitabine in
patients with metastatic breast cancer pretreated
with anthracyclines and taxanes. Clin Breast
Cancer 2005;6(2):158-62. Abstract
Bajetta E et al. Safety and efficacy of two
different doses of capecitabine in the treatment
of advanced breast cancer in older women. J Clin Oncol 2005;23(10):2155-61. Abstract
Baweja M et al. Phase II trial of oral vinorelbine
for treatment of metastatic breast cancer in
women 65 years and older: N003A. Proc ASCO 2005;Abstract 740.
Bayo J et al. Docetaxel followed by capecitabine
as first-line chemotherapy in metastatic breast
cancer patients: Preliminary results. Proc ASCO 2005;Abstract 854.
Berruti A et al. Paclitaxel, vinorelbine and 5-
fluorouracil in breast cancer patients pretreated
with adjuvant anthracyclines. Br J Cancer
2005;92(4):634-8. Abstract
Biganzoli L et al. Doxorubicin and paclitaxel
versus doxorubicin and cyclophosphamide as
first-line chemotherapy in metastatic breast
cancer: The European Organization for
Research and Treatment of Cancer 10961
Multicenter Phase III Trial. J Clin Oncol 2002;20(14):3114-21. Abstract
Blum JL et al. A Phase II trial of combination
therapy with capecitabine (C) and weekly
paclitaxel (P) for metastatic breast cancer
(MBC): Preliminary results in taxane-naive
patients. Poster presentation. San Antonio Breast
Cancer Symposium 2004;Abstract 5053.
Blum JL et al. ABI-007 nanoparticle paclitaxel:
Demonstration of anti-tumor activity in taxanerefractory
metastatic breast cancer. Proc ASCO 2003;Abstract 64.
Bontenbal M et al. Phase II to III study
comparing doxorubicin and docetaxel
with fluorouracil, doxorubicin, and
cyclophosphamide as first-line chemotherapy in
patients with metastatic breast cancer: Results
of a Dutch Community Setting Trial for the
Clinical Trial Group of the Comprehensive
Cancer Centre. J Clin Oncol 2005;23(28):7081-8.
Abstract
Bria E et al. Impact of taxanes in association
with anthracyclines in 1st line chemotherapy for metastatic breast cancer (MBC): Comprehensive
review of 2805 patients in 7 phase III trials. Proc ASCO 2004;Abstract 659.
Chan S et al. Gemcitabine plus docetaxel
(GD) versus capecitabine plus docetaxel
(CD) for anthracycline-pretreated metastatic
breast cancer (MBC) patients (pts): Results
of a European phase III study. Proc ASCO 2005;Abstract 581.
Chun JH et al. Frontline docetaxel (T)/
capecitabine (X) combination therapy in patients
(pts) with metastatic breast cancer (MBC): A
phase II study. Proc ASCO 2004;Abstract 778.
Clemons MJ et al. Palliative chemotherapy with
vinorelbine or capecitabine in women with
anthracycline and taxane refractory metastatic
breast cancer. Proc ASCO 2004;Abstract 773.
Estevez LG et al. Phase II study with the combination
of capecitabine (C) and vinorelbine (V)
in metastatic breast cancer (MBC) previously
treated with anthracyclines and taxanes. Proc ASCO 2004;Abstract 748.
Evans TR et al. Phase III randomized trial of
doxorubicin and docetaxel versus doxorubicin
and cyclophosphamide as primary medical
therapy in women with breast cancer: An angloceltic
cooperative oncology group study. J Clin Oncol 2005;23(13):2988-95. Abstract
Feher O et al. First-line gemcitabine versus
epirubicin in postmenopausal women aged 60
or older with metastatic breast cancer: A multicenter,
randomized, phase III study. Ann Oncol 2005;16(6):899-908. Abstract
Ghosn M et al. Vinorelbine (N)-capecitabine (C)
combination in advanced breast cancer (ABC):
Long-term results of two multicentric phase II
trials. Proc ASCO 2005;Abstract 673.
Gradishar WJ et al. Phase III trial of
nanoparticle albumin-bound paclitaxel
compared with polyethylated castor oil-based
paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-7803. Abstract
Gradishar WJ et al. Capecitabine plus paclitaxel
as front-line combination therapy for metastatic
breast cancer: A multicenter phase II study. J Clin Oncol 2004;22(12):2321-7. Abstract
Gralow J et al. SWOG S0102: A phase II study
of docetaxel (DOC) and vinorelbine (VNR) +
filgrastim for HER-2 negative, stage IV breast
cancer. Proc ASCO 2005;Abstract 567.
Grecea D et al. A phase II study of weekly or
3-weekly docetaxel in patients with metastatic
breast cancer. Proc ASCO 2005;Abstract 736.
Ibrahim NK et al. Multicenter phase II trial
of ABI-007, an albumin-bound paclitaxel, in
women with metastatic breast cancer. J Clin Oncol 2005;23(25):6019-26. Abstract
Jones SE et al. Randomized phase III study of
docetaxel compared with paclitaxel in metastatic
breast cancer. J Clin Oncol 2005;23(24):5542-51.
Abstract
Jones S et al. Randomized trial comparing
docetaxel and paclitaxel in patients with
metastatic breast cancer. Breast Cancer Res Treat 2003;Abstract 10.
Katsumata N et al. Phase III trial of doxorubicin
(A)/cyclophosphamide (C) (AC), docetaxel (D),
and alternating AC and D (AC-D) as frontline
chemotherapy for metastatic breast cancer
(MBC): Japan Clinical Oncology Group trial
(JCOG9802). Proc ASCO 2005;Abstract 521.
Lim H et al. A phase II study of docetaxel (T)
and capecitabine (X) combination chemotherapy
as first-line chemotherapy for patients (pts) with
metastatic breast cancer (MBC). Proc ASCO 2005;Abstract 889.
Miller KD et al. E2100: A randomized phase III
trial of paclitaxel versus paclitaxel plus bevacizumab
as first-line therapy for locally recurrent
or metastatic breast cancer. Presentation. Proc ASCO 2005. No abstract available
Miller KD et al. Randomized phase III trial
of capecitabine compared with bevacizumab
plus capecitabine in patients with previously
treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract
Minea LN et al. Capecitabine monotherapy for
elderly patients with metastatic breast cancer. Proc ASCO 2004;Abstract 797.
Moinpour C et al. Gemcitabine plus paclitaxel
(GT) versus paclitaxel (T) as first-line treatment
for anthracycline pre-treated metastatic
breast cancer (MBC): Quality of life (QoL) and
pain palliation results from the global phase III
study. Proc ASCO 2004;Abstract 621.
Moulder SL et al. Results of a planned
efficacy and safety analysis for a National
Comprehensive Cancer Network sponsored
phase II study of gemcitabine and irinotecan
(GI) in metastatic breast cancer (MBC). Proc ASCO 2005;Abstract 679.
Nabholtz JM et al; TAX 306 Study Group.
Docetaxel and doxorubicin compared with
doxorubicin and cyclophosphamide as first-line
chemotherapy for metastatic breast cancer:
Results of a randomized, multicenter, phase III
trial. J Clin Oncol 2003;21(6):968-75. Abstract
Nole F et al. Dose finding and pharmacokinetic
study of an all-oral combination regimen of oral
vinorelbine and capecitabine in metastatic breast
cancer (MBC) patients: Final results. Proc ASCO 2005;Abstract 666.
O’Shaughnessy JA et al. Weekly nanoparticle
albumin paclitaxel (Abraxane) results in
longterm disease control in patients with taxanerefractory
metastatic breast cancer. San Antonio
Breast Cancer Symposium 2004;Abstract 1070.
O’Shaughnessy J et al. Superior survival with
capecitabine plus docetaxel combination therapy
in anthracycline-pretreated patients with
advanced breast cancer: Phase III trial results. J Clin Oncol 2002;20(12):2812-23. Abstract
Paley M et al. Preferences for oral and parenteral
antitumor therapy: A survey of 260 patients
with metastatic breast cancer. Proc ASCO 2005;Abstract 619.
Palmeri S et al. Weekly docetaxel and
gemcitabine as first-line treatment for metastatic
breast cancer: Results of a multicenter phase II
study. Oncology 2005;68(4-6):438-45. Abstract
Perez EA et al. A phase II trial of docetaxel
and carboplatin as first-line chemotherapy for
metastatic breast cancer: NCCTG study N9932. Oncology 2005;69(2):117-21. Abstract
Pierga JY et al; Cooperative Group of the French
capecitabine compassionate use program. Efficacy
and safety of single agent capecitabine in
pretreated metastatic breast cancer patients
from the French compassionate use program. Breast Cancer Res Treat 2004;88(2):117-29.
Abstract
Rossi A et al. Single agent vinorelbine as first-line
chemotherapy in elderly patients with advanced
breast cancer. Anticancer Res 2003;23(2C):1657-
64. Abstract
Segalla JGM et al. Effect of capecitabine (X)
on quality of life (QoL) in patients (pts) with
metastatic breast cancer (MBC). Proc ASCO 2004;Abstract 8130.
Seidman AD et al. CALGB 9840: Phase III
study of weekly (W) paclitaxel (P) via 1-hour(h)
infusion versus standard (S) 3h infusion every
third week in the treatment of metastatic breast
cancer (MBC), with trastuzumab (T) for HER2
positive MBC and randomized for T in HER2
normal MBC. Proc ASCO 2004;Abstract 512.
Seidman AD et al. Single-agent capecitabine:
A reference treatment for taxane-pretreated
metastatic breast cancer? Oncologist 2002;7(Suppl
6):20-8. Abstract
Sikov WM et al. Gemcitabine and capecitabine
in metastatic breast cancer (MBC): A Brown
University Oncology Group (BrUOG) phase II
study. Proc ASCO 2005;Abstract 785.
Sledge GW et al. Phase III trial of doxorubicin,
paclitaxel, and the combination of doxorubicin
and paclitaxel as front-line chemotherapy
for metastatic breast cancer: An Intergroup
trial (E1193). J Clin Oncol 2003;21(4):588-92.
Abstract
Stemmler J et al. High efficacy and low toxicity of
weekly docetaxel given as first-line treatment for
metastatic breast cancer. Oncology 2005;68(1):71-
8. Abstract
Talbot DC et al. Randomised, phase II trial
comparing oral capecitabine (Xeloda) with
paclitaxel in patients with metastatic/advanced
breast cancer pretreated with anthracyclines. Br
J Cancer 2002;86(9):1367-72. Abstract
Tong DK et al. Phase II study of an ‘all-oral’
regimen of capecitabine, idarubicin and
cyclophosphamide for metastatic breast cancer
— Safety, efficacy and quality of life. Oncology 2005;68(4-6):520-5. Abstract
Vukelja S et al. Activity of oral irinotecan (IRI)
in metastatic breast cancer (MBC) patients after
prior anthracycline, taxane and capecitabine:
Phase 2 study results. Proc ASCO 2005;Abstract 562.
Winer EP et al. Failure of higher-dose paclitaxel
to improve outcome in patients with metastatic
breast cancer: Cancer and leukemia group B trial
9342. J Clin Oncol 2004;22(11):2061-8. Abstract
Zamora P et al. Capecitabine (X) as single agent
in elderly patients (p) with metastatic breast
cancer (MBC). Proc ASCO 2005;Abstract 843.
Zielinski C et al. Gemcitabine, epirubicin, and
paclitaxel versus fluorouracil, epirubicin, and
cyclophosphamide as first-line chemotherapy in
metastatic breast cancer: A Central European
Cooperative Oncology Group International,
multicenter, prospective, randomized phase III
trial. J Clin Oncol 2005;23(7):1401-8. Abstract
|